Global Acquired Orphan Blood Diseases Therapeutics Market to Reach USD 18.1 Billion by 2033, Catalyzed by Rapid Advancements in Medical Research

December 23, 2024 | Healthcare

VIEW FULL TABLE OF CONTENTS

According to the latest report by IMARC Group, titled “Acquired Orphan Blood Diseases Therapeutics Market Report by Therapy (Recombinant Factor, Immunoglobulin Infusion Therapy, Activated Prothrombin Complex Concentrate, Thrombopoietin Receptor Agonists, and Others), Disease Indication (Acquired Agranulocytosis, Acquired Hemophilia, Acquired Von Willebrand Syndrome, Paroxysmal Nocturnal Hemoglobinuria (PNH), Myelodysplastic Syndrome, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Others), and Region 2025-2033,” the global acquired orphan blood diseases therapeutics market size reached USD 9.5 Billion in 2024. Acquired orphan blood disease therapeutics refers to the specialized medical treatments designed for rare blood disorders that are developed post-birth. They include a range of treatment modalities, such as targeted therapies, biologics, small molecule inhibitors, and gene therapies. Acquired orphan blood disease therapeutics are engineered to combat specific aspects of the disorder by utilizing complex biological components, proteins, or synthetic molecules. They are employed in hospitals, specialized treatment centers, and research institutions. Acquired orphan blood disease therapeutics offer numerous benefits, including early intervention, personalized treatment plans, improved patient quality of life, minimized disease progression, and curative possibilities. Additionally, they offer reduced side effects, targeted drug delivery, quicker recovery, cost-effectiveness in long-term disease management, and an increased treatment success rate.

Global Acquired Orphan Blood Diseases Therapeutics Market Trends:

The rapid advancements in medical research contributing to the identification and development of effective and targeted treatments for acquired orphan blood diseases, are major factors propelling the market growth. Moreover, the implementation of government policies and incentives, such as exclusive marketing rights and tax credits that encourage pharmaceutical companies to invest in research and innovation initiatives, is supporting the market growth. Along with this, the growing awareness and advocacy efforts by patient organizations and healthcare providers to educate the public and policy-makers about the critical need for treatment is stimulating the market growth. Besides this, rapid advances in genomic and proteomic technologies leading to the precise identification of disease etiologies are anticipated to drive the market growth. Furthermore, the rising partnerships and collaborations among research institutions, pharmaceutical companies, and healthcare providers for sharing knowledge, resources, and financial risks that accelerate the development and distribution of therapeutics are bolstering the market growth. In addition to this, the increasing establishment of specialized healthcare facilities and the availability of skilled professionals that serve to decentralize treatment, making it more accessible to a broader patient base, is acting as a growth-inducing factor. Apart from this, the rising prevalence of personalized medicine and the growing focus on patient-centric care models are also favoring the market growth. In line with this, the sudden shift towards value-based healthcare that impacts reimbursement policies, making it financially viable for healthcare providers and patients to opt for advanced treatment options, is creating remunerative growth opportunities for the market. Looking forward, the market value is projected to reach USD 18.1 Billion by 2033, expanding at a CAGR of 7.13% during 2025-2033.

Market Summary:

Based on the therapy, the market has been divided into recombinant factor, immunoglobulin infusion therapy, activated prothrombin complex concentrate, thrombopoietin receptor agonists, and others.
On the basis of the disease indication, the market has been classified into acquired agranulocytosis, acquired hemophilia, acquired von willebrand syndrome, paroxysmal nocturnal hemoglobinuria (PNH), myelodysplastic syndrome, and others. According to the report, acquired hemophilia accounted for the largest market share.
Based on the distribution channel, the market has been categorized into hospital pharmacy, retail pharmacy, and others. Amongst these, hospital pharmacy accounted for the largest market share.
Region-wise, the market has been segmented into North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America was the largest market for acquired orphan blood diseases therapeutics.
The competitive landscape of the market has also been examined, with some of the key players being Alexion Pharmaceuticals Inc. (AstraZeneca plc), Amgen Inc., GSK plc, Novartis AG, Novo Nordisk A/S, Otsuka Pharmaceutical Co. Ltd., Rigel Pharmaceuticals Inc., Roche Holding AG, Sanofi, Takeda Pharmaceutical Company Limited, etc.

Report Coverage:

Report Features	Details
Base Year of the Analysis	2024
Historical Period	2019-2024
Forecast Period	2025-2033
Units	Billion USD
Scope of the Report	Exploration of Historical and Forecast Trends, Industry Catalysts and Challenges, Segment-Wise Historical and Predictive Market Assessment: Therapy Disease Indication Distribution Channel Region
Therapies Covered	Recombinant Factor, Immunoglobulin Infusion Therapy, Activated Prothrombin Complex Concentrate, Thrombopoietin Receptor Agonists, Others
Disease Indications Covered	Acquired Agranulocytosis, Acquired Hemophilia, Acquired Von Willebrand Syndrome, Paroxysmal Nocturnal Hemoglobinuria (PNH), Myelodysplastic Syndrome, Others
Distribution Channels Covered	Hospital Pharmacy, Retail Pharmacy, Others
Regions Covered	Asia Pacific, Europe, North America, Latin America, Middle East and Africa
Countries Covered	United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico
Companies Covered	Alexion Pharmaceuticals Inc. (AstraZeneca plc), Amgen Inc., GSK plc, Novartis AG, Novo Nordisk A/S, Otsuka Pharmaceutical Co. Ltd., Rigel Pharmaceuticals Inc., Roche Holding AG, Sanofi, Takeda Pharmaceutical Company Limited, etc.
Customization Scope	10% Free Customization
Post-Sale Analyst Support	10-12 Weeks
Delivery Format	PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)

About Us:

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Contact Us:

IMARC Group
134 N 4th St.
Brooklyn, NY 11249, USA
Email: Sales@imarcgroup.com
Americas:- +1 631 791 1145 | Africa and Europe :- +44-753-713-2163 | Asia: +91-120-433-0800

Need more help?

Speak to our experienced analysts for insights on the current market scenarios.
Include additional segments and countries to customize the report as per your requirement.
Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
For further assistance, please connect with our analysts.

Global Acquired Orphan Blood Diseases Therapeutics Market to Reach USD 18.1 Billion by 2033, Catalyzed by Rapid Advancements in Medical Research

Purchase Options New Year Sale

Inquire Before Buying

Benefits of Customization

Personalize this research
Triangulate with your data
Get data as per your format and definition
Gain a deeper dive into a specific application, geography, customer, or competitor
Any level of personalization

Speak to an Analyst

Request Brochure

Get in Touch With Us

UNITED STATES

Phone: +1-631-791-1145

INDIA

Phone: +91-120-433-0800

UNITED KINGDOM

Phone: +44-753-714-6104

Email: sales@imarcgroup.com

Client Testimonials

IMARC made the whole process easy. Everyone I spoke with via email was polite, easy to deal with, kept their promises regarding delivery timelines and were solutions focused. From my first contact, I was grateful for the professionalism shown by the whole IMARC team. I recommend IMARC to all that need timely, affordable information and advice. My experience with IMARC was excellent and I can not fault it.

The IMARC team was very reactive and flexible with regard to our requests. A very good overall experience. We are happy with the work that IMARC has provided, very complete and detailed. It has contributed to our business needs and provided the market visibility that we required

We were very happy with the collaboration between IMARC and Colruyt. Not only were your prices competitive, IMARC was also pretty fast in understanding the scope and our needs for this project. Even though it was not an easy task, performing a market research during the COVID-19 pandemic, you were able to get us the necessary information we needed. The IMARC team was very easy to work with and they showed us that it would go the extra mile if we needed anything extra

Last project executed by your team was as per our expectations. We also would like to associate for more assignments this year. Kudos to your team.

We would be happy to reach out to IMARC again, if we need Market Research/Consulting/Consumer Research or any associated service. Overall experience was good, and the data points were quite helpful.

Arabian Plastic Manufacturing Company Ltd.

The figures of market study were very close to our assumed figures. The presentation of the study was neat and easy to analyse. The requested details of the study were fulfilled. My overall experience with the IMARC Team was satisfactory.

The overall cost of the services were within our expectations. I was happy to have good communications in a timely manner. It was a great and quick way to have the information I needed.

My questions and concerns were answered in a satisfied way. The costs of the services were within our expectations. My overall experience with the IMARC Team was very good.

I agree the report was timely delivered, meeting the key objectives of the engagement. We had some discussion on the contents, adjustments were made fast and accurate. The response time was minimum in each case. Very good. You have a satisfied customer.

We would be happy to reach out to IMARC for more market reports in the future. The response from the account sales manager was very good. I appreciate the timely follow ups and post purchase support from the team. My overall experience with IMARC was good.

IMARC was a good solution for the data points that we really needed and couldn't find elsewhere. The team was easy to work, quick to respond, and flexible to our customization requests.

IMARC did an outstanding job in preparing our study. They were punctual and precise, delivering all the data we required in a clear and well-organized format. Their attention to detail and ability to meet deadlines was impressive, making them a reliable partner for our project.

I wanted to express my sincere appreciation for your efforts in handling this matter. Your dedication and commitment have truly been commendable. It is evident that you have put in a tremendous amount of hard work and expertise into resolving the issues at hand. I would also like to take this opportunity to inform you that we are greatly interested

Overall, the deliverable was well organized and my experience with the project team was good. In particular, I appreciated how they responded when I requested additional information and the Japanese version.

The IMARC team were extremely professional and very cooperative. The team were also extremely flexible in making changes and modifications wherever required. The entire experience right from project kick-off to after sales support was fruitful and smooth.

I’d like to express my gratitude for the work you accomplished with the industry report. The way you responded to the requirements and delivered under tight timelines shows your expertise, exceptional work ethic and commitment to your customer’s success. The entire team and company are incredibly thankful for your dedication. Once again, thank you

The market reports from IMARC have been instrumental in guiding our business strategies. We found the reports comprehensive and data-driven, which helped us make informed decisions. The detailed insights and actionable data have consistently provided us with a competitive edge in a rapidly changing alcohol market.

One of the best things about IMARC is their flexibility and predisposition to tailor the reports and adapt to our needs. They are not just great in their researching and consulting solutions, but their service is unparallelled. We’ve worked with them a couple of times and we will keep working with them in future projects.

We recently commissioned multiple market research reports from IMARC, and the insights we received were invaluable. The depth of analysis, accuracy of data, and actionable recommendations have greatly enhanced our strategic decision-making.

The market estimates provided by your team were pretty much in line with what we were theorizing internally. Really appreciate the work on this.

The sale account manager and the service was excellent. The data and market trends gathered from the report was insightful and really assisted while planning future product and growth strategies.

The report is excellent and has good amount of data and our team is extremely happy with the information provided.

Thank you very much for your cooperation and post purchase support. We were really happy with the final deliverable, and the takeaways from the report.